Effect of carvedilol on echocardiographic ejection fraction and fraction shortening in doxorubicin treated females with breast cancer | ||
| Al-Qadisiah Medical Journal | ||
| Article 1, Volume 8, Issue 1, June 2012, Pages 133-142 PDF (0 K) | ||
| Authors | ||
| Hashim Mahdi Hashim; Adeeb Ahmad Al-Zubaidy; Sameer Hassan Abboud Al-Rekabi | ||
| Abstract | ||
| Background : Doxorubicin based regimen is the most common treatment of breast cancer which is highly complicated by cardiotoxicity. Aim : To clarify the possible effects of carvedilol on echocardiographic ejection fraction and fraction shortening in doxorubicin based regimen in females with breast cancer. Patients and Methods : A total of 16 females with breast cancer were included in this study. The patients were randomized into 2 groups , 8 patients each. Group I included patients were treated with doxorubicin based regimen for 6 cycles with 21 day apart. Group II included patients were received doxorubicin based regimen with carvedilol 3.125 mg , orally , twice daily for 5 days , for 6 cycles. Echocardiography was done to measure ejection fraction and fraction shortening at zero time and 3 days after 2nd , 4th and 6th cycles. Results: Treatment with CAF regimen caused highly significant decrease in echocardiographic ejection fraction and fraction shortening after 2nd , 4th and 6th cycles in comparison to baseline readings ( P < 0.01 ). Combined CAF + Carvedilol 3.125 mg orally twice daily for 5 days caused highly significant increment in echocardiographic ejection fraction and fraction shortening compared with that of CAF regimen group ( P < 0.01 ). Conclusion: Carvedilol causes significant increase in echocardiographic ejection fraction and fraction shortening in doxorubicin treated patients. | ||
| Keywords | ||
| Carvedilol; Doxorubicin; Cardiotoxicity; Ejection fraction; Fraction Shortening | ||
|
Statistics Article View: 90 PDF Download: 38 |
||